This week, we explore how academics have been spending their time during the COVID-19 pandemic and the impact this is having on scholarly publishing now and in the future. We also look at the report from the 8th EMWA Symposium. Finally, we ‘Poké’ a bit of fun at predatory journals.
This week, we explore the importance of data sharing in COVID-19, Alzheimer’s disease and social psychology research. We also look at trends in open access publishing across the globe and focus on open access initiatives in Africa. Finally, we learn the ideal frequency for the word ‘and’.
Featuring a rundown of the latest results from EU Trials Tracker, how pharma could help make vaccine clinical trials trustworthy again, a survey of researchers’ attitudes towards peer reviewing, the citation advantage of preprints, the next consortium to commit to open science and a reminder of the EMWA virtual events.
Featuring the experiences of an open science advocate in pharma, an analysis of open science and diversity, an undergraduate peer-reviewed journal, the lessons learnt from COVID-19, alternatives to journal impact factors and a machine-learning approach to big data.
Featuring discussions of open scholarship, plain language summaries of publications, support for rapid reviews of COVID-19 preprints, the Arabian Citation Index, the outlook of open access, Brazilian publication policies and a celebration of HighWire.
Featuring discussions about patient partnerships in research, the curious case of MDPI, rapid reviews of COVID-19 preprints, metrics of open access papers, recognition for research contributors, the implementation of new editorial procedures and a publisher’s steps towards open access.
Featuring the impact COVID-19 could have on evidence-based medicine, the use of open science and the economic landscape of publishing, the results of a survey on attitudes towards preprints, the first COVID-19 preprint index, the importance of open data to patients and a call for the revision of academic career progression.
Featuring a win for transparency advocates in a federal lawsuit, the new ICMJE disclosure form, framework from cOAlition S on hybrid journals, inequalities in open access publishing, the future of scientific papers, ethical research practice, and clearing up the differences between Open Science and Open Access.
Featuring the debunking of ‘fake news’, cardiovascular clinical trial controversy, open data in the USA, reduced lack of funding for preprint repositories, the wait for the launch of the Projekt DEAL and Wiley flagship journal, ranking and indices in science, and questions surrounding Plan S.
Featuring stakeholder opinions on the proposed White House Executive Order on open access in the USA, a new data-sharing declaration and the introduction of a financial incentive for publishing negative results in Germany